Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PB307
- Development stage
- Preclinical
- Lead developer
- Contineum Therapeutics
01
Overview
PB307 is an immuno-oncology biologic developed by PEG Biosciences designed to harness the body's immune system to combat various malignancies. The agent works by modulating the tumor microenvironment, specifically by increasing the density of tumor-infiltrating lymphocytes (TILs) and reducing immunosuppressive components that typically shield tumors from immune detection. Preclinical studies in animal models have demonstrated that PB307 can inhibit cancer cell growth and promote a sustained, enhanced immune response. It is currently being investigated for a broad range of indications, including pancreatic, breast, colorectal, gastric, brain, liver, ovarian, and lung cancers.
Beyond the preview
Go deeper on PB307.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PB307.